Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-15T02:45:48.934Z Has data issue: false hasContentIssue false
  • English
  • Français

Implementation of a Market Entry Reward within the United States

Published online by Cambridge University Press:  01 January 2021

Gregory W. Daniel ,
Monika Schneider ,
Marianne Hamilton Lopez  and
Mark B. McClellan
Get access Rights & Permissions [Opens in a new window]

Extract

As part of a multifactorial approach to address weak incentives for innovative antimicrobial drug development, market entry rewards (MERs) are an emerging solution. Recently, the Duke-Margolis Center for Health Policy released the Priority Antimicrobial Value and Entry (PAVE) Award proposal, which combines a MER with payment reforms, transitioning from volume-based to “value-based” payments for antimicrobials. Here, the PAVE Award and similar MERs are reviewed, focusing on further refinement and avenues for implementation.

Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 46 , Issue S1: Incentives to Stimulate Research and Development of New Antibiotics: Detailed Assessments of Select Incentives and Models , Spring 2018 , pp. 50 - 58
Copyright
Copyright © American Society of Law, Medicine and Ethics 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Centers for Diseases Control and Prevention, Antibiotic Resistance Threats in the United States, 2013 (2013).Google Scholar
Boucher, H. W., Talbot, G. H., Benjamin, J. Jr., Bradley, D. K., Guidos, R. J., Jones, R. N., Murray, B. E., Bonomo, R. A., Gilbert, D., and the Infectious Diseases Society of America, “10 x ‘20 Progress--Development of New Drugs Active against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America,” Clinical Infectious Diseases 56, no. 12 (2013): 1685–1694; Pew Charitable Trusts, Tracking the Pipeline of Antibiotics in Development, available at <http://www.pewtrusts.org/en/research-and-analysis/issuebriefs/2014/03/12/tracking-the-pipeline-of-antibiotics-in-development> (last visited March 21, 2018).Google Scholar
Sertkaya, A., Eyraud, J., Birkenbach, A., Franz, C., Ackerley, N., Overton, V., and Outterson, K., Analytical Framework for Examining the Value of Antibacterial Products, of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services (April 14, 2014); Infectious Diseases Society of America, No New Drugs to Combat Antimicrobial Resistant Bugs, available at <http://www.idsociety.org/uploadedFiles/IDSA/Global/IDSA%20Antibiotic%20Incentives%20Infographic%202016.pdf> (last visited March 21, 2018); QuintilesIMS Institute, Medicines Use and Spending in the U.S. A Review of 2015 and Outlook to 2020, available at <https://www.iqvia.com/institute/reports/medicines-use-and-spending-in-the-us-a-review-of-2016> (last visited March 21, 2018).Google Scholar
Centers for Disease Control and Prevention, “Core Elements of Hospital Antibiotic Stewardship Programs,” available at <https://www.cdc.gov/antibiotic-use/healthcare/implementation/core-elements.html> (last visited March 21, 2018).+(last+visited+March+21,+2018).>Google Scholar
Chatham House Working Group on New Antibiotic Business Models, Towards a New Global Business Model for Antibiotics, available at <https://www.chathamhouse.org/sites/files/chathamhouse/field/field_document/20151009NewBusinessModelAntibioticsCliftGopinathanMorelOuttersonRottingenSo.pdf> (last visited March 21, 2018); J. O'Neill, Tackling Drug-Resistant Infections Globally: Final Report and Recommendations, available at <https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf> (last visited March 21, 2018); S. Stern, S. Chorzelski, L. Franken, S. V. ller, H. Rentmeister, and B. Grosch, Breaking through the Wall - A Call for Concerted Action on Antibiotics Research and Development, The German Federal Ministry of Health (February 2017); DRIVE-AB Final Report, “Revitalizing the Antibiotic Pipeline: Stimulating Innovation While Driving Sustainable Use and Global Access,” 2018, available at <http://www.imi.europa.eu/projects-results/project-fact-sheets/drive-ab> (last visited March 21, 2018). (last visited March 21, 2018); S. Stern, S. Chorzelski, L. Franken, S. V. ller, H. Rentmeister, and B. Grosch, Breaking through the Wall - A Call for Concerted Action on Antibiotics Research and Development, The German Federal Ministry of Health (February 2017); DRIVE-AB Final Report, “Revitalizing the Antibiotic Pipeline: Stimulating Innovation While Driving Sustainable Use and Global Access,” 2018, available at (last visited March 21, 2018).' href=https://scholar.google.com/scholar?q=Chatham+House+Working+Group+on+New+Antibiotic+Business+Models,+Towards+a+New+Global+Business+Model+for+Antibiotics,+available+at++(last+visited+March+21,+2018);+J.+O'Neill,+Tackling+Drug-Resistant+Infections+Globally:+Final+Report+and+Recommendations,+available+at++(last+visited+March+21,+2018);+S.+Stern,+S.+Chorzelski,+L.+Franken,+S.+V.+ller,+H.+Rentmeister,+and+B.+Grosch,+Breaking+through+the+Wall+-+A+Call+for+Concerted+Action+on+Antibiotics+Research+and+Development,+The+German+Federal+Ministry+of+Health+(February+2017);+DRIVE-AB+Final+Report,+“Revitalizing+the+Antibiotic+Pipeline:+Stimulating+Innovation+While+Driving+Sustainable+Use+and+Global+Access,”+2018,+available+at++(last+visited+March+21,+2018).>Google Scholar
Outterson, K., Gopinathan, U., Clift, C., So, A. D., Morel, C. M., and Røttingen, J.-A., “Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality,” PLOS Medicine 13, no. 6 (June 14, 2016): e1002043.CrossRefGoogle Scholar
Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB), Recommendations for Incentivizing the Development of Vaccines, Diagnostics, and Therapeutics to Combat Antibiotic-Resistance (September 2017).Google Scholar
Improving Access to Affordable Prescription Drugs Act, S.771, 115th Cong. (2017); Improving Access to Affordable Prescription Drugs Act, HR.1776, 115th Cong. (2017).Google Scholar
Daniel, G. W., McClellan, M. B., Schneider, M., Qian, J., Lavezzari, G., and de Graffenreid, E., “Value-Based Strategies for Encouraging New Development of Antimicrobial Drugs,” available at <https://healthpolicy.duke.edu/PAVE> (last visited March 21, 2018).+(last+visited+March+21,+2018).>Google Scholar
Daniel, G. W. et al., Value-Based Strategies for Encouraging New Development of Antimicrobial Drugs, Robert J. Margolis, MD, Center for Health Policy at Duke University, available at <https://healthpolicy.duke.edu/sites/default/files/atoms/files/value-based_strategies_for_encouraging_new_development_of_antimicrobial_drugs.pdf> (last visited March 19, 2018).+(last+visited+March+19,+2018).>Google Scholar
See CDC Report, supra note 1; World Health Organization, “Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics,” available at <http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/ (last visited March 21, 2018).Google Scholar
Rex, J. H. and Outterson, K., “Antibiotic Reimbursement in a Model Delinked from Sales: A Benchmark-Based Worldwide Approach,” The Lancet Infectious Disease 16, no. 4 (2016): 500–505.CrossRefGoogle Scholar
Kaiser, J., “NIH Gets $2 Billion Boost in Senate Spending Bill,” Science, June 7, 2016.CrossRefGoogle Scholar
Office of the Assistant Secretary for Preparedness and Response, “ASPR Blog Series: Combatting Antibiotic Resistance — PHE,” available at <http://www.phe.gov/about/barda/Pages/antibiotic-resistance.aspx> (last visited March 21, 2018).+(last+visited+March+21,+2018).>Google Scholar
See Improving Access to Affordable Prescription Drugs Act, supra note 8.Google Scholar
CARB-X, “About CARB-X,” available at <http://www.carb-x.org/about> (last visited March 21, 2018).+(last+visited+March+21,+2018).>Google Scholar
Kaitin, K. I. and DiMasi, J. A., “Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade,” Clinical Pharmacology & Therapeutics 89, no. 2 (2011): 183–188.CrossRefGoogle Scholar
Outterson, K. and McDonnell, A., “Funding Antibiotic Innovation with Vouchers: Recommendations on How to Strengthen a Flawed Incentive Policy,” Health Affairs 35, no. 5 (2016): 784–790.CrossRefGoogle Scholar
Id.Google Scholar
See O'Neill, supra note 5.Google Scholar
See PACCARB, supra note 7; Ferraro, J. S., Towse, A., Mestre-Ferrandiz, J., “Incentives for New Drugs to Tackle Anti-Microbial Resistance,” available at <https://www.ohe.org/publications/incentives-new-drugs-tackle-anti-microbial-resistance> (last visited January 9, 2018).+(last+visited+January+9,+2018).>Google Scholar
See Rex, supra note 12.Google Scholar